Valuation: Delcath Systems, Inc.

Market Cap 442M 386M 357M 329M 620M 42.59B 633M 4.26B 1.68B 20.86B 1.66B 1.62B 71.8B P/E 2026 *
-22.6x
P/E 2027 * -23.7x
Enterprise Value 442M 386M 357M 329M 620M 42.59B 633M 4.26B 1.68B 20.86B 1.66B 1.62B 71.8B EV / Sales 2026 *
4.28x
EV / Sales 2027 * 3.39x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-1.54%
Current month+1.75%
1 month+7.38%
3 months+17.96%
6 months+23.53%
Current year+26.83%
1 week 12.32
Extreme 12.32
13.29
1 month 11.35
Extreme 11.35
13.74
Current year 8.48
Extreme 8.485
13.74
1 year 8.12
Extreme 8.12
13.74
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
1,000,000
Manager TitleAgeSince
Chief Executive Officer 62 30/09/2020
Director of Finance/CFO 47 30/04/2023
Chief Operating Officer 55 17/03/2024
Director TitleAgeSince
Chairman 62 15/02/2023
Director/Board Member 70 13/02/2020
Director/Board Member 60 05/05/2020
Date Insider Type Main position Quantity % Market Cap.
13/05/26 Free

Director

22,500 0.0646%
13/05/26 Free

Chairman

22,500 0.0646%
13/05/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-1.54%+13.16%+164.12% 442M
-0.99%-5.74%-5.43%-29.77% 19.61B
-0.87%+1.18%-10.70%-12.48% 15.13B
-3.07%-1.76%-61.10%-48.62% 5.46B
-0.86%+14.77% - - 4.21B
0.00%+0.95%-18.46%-14.52% 1.73B
-2.49%+1.43%+38.77%+8.69% 1.62B
-5.54%-0.70%-40.85%-61.41% 1.18B
-2.00%+6.37%+77.11%+131.86% 876M
-8.35%-13.56% - - 239M
Average -2.45%+0.04%-0.94%+17.23% 5.05B
Weighted average by Cap. -1.33%-0.76%-11.84%-20.27%

Financials

2026 *2027 *
Net sales 103M 90.22M 83.26M 76.74M 145M 9.94B 148M 995M 391M 4.87B 388M 379M 16.76B 131M 114M 105M 97.1M 183M 12.58B 187M 1.26B 495M 6.16B 491M 480M 21.21B
Net income -21.04M -18.39M -16.97M -15.64M -29.48M -2.03B -30.14M -203M -79.78M -993M -79.03M -77.3M -3.42B -20M -17.48M -16.13M -14.87M -28.02M -1.93B -28.65M -193M -75.83M -943M -75.12M -73.47M -3.25B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
17/07/26 US$12.81 -0.31% 369,326
16/07/26 US$12.85 -2.50% 378,382
15/07/26 US$13.18 +0.30% 315,578
14/07/26 US$13.14 +2.10% 281,694
13/07/26 US$12.87 -1.08% 389,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.81USD
Average target price
21.55USD
Spread / Average Target
+68.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock